Bayer has won first-line approval for its tyrosine kinase inhibitor, Hyrnuo, in patients with HER2-mutant non-small cell lung cancer. The green light comes around half a year after a similar nod for rival TKI med Hernexeos from Boehringer Ingelheim.

The 60-second ad sees “Yellowstone” actor Kevin Costner doing the math on the benefits of early cancer detection with Caris’ Caris Detect blood test.

Merck continues sweeping staff reductions, laying off 54 at its Rahway headquarters. The staff changes are set to take effect in December and January.

With a phase 3 win now fleshed out and an FDA filing recently submitted, BioMarin is advancing expansion plans for Voxzogo, looking to extend the dwarfism drug’s reach as it faces new pressure in its inaugural achondroplasia indication.

In a stabilizing move, the Department of Health and Human Services announced Tuesday afternoon that it has tapped Michael Davis, M.D., Ph.D., and Karim Mikhail—who’ve been serving as acting directors of CDER and CBER, respectively—to occupy their posts on a permanent basis.

Exclusive insights from the Patients as Partners Advisory Board on the biggest challenges and opportunities shaping patient engagement, patient advocacy, clinical trial participation, trust, transparency, and patient-focused drug development.